The investigations of efficacy and appropriate vaccination for trivalent influenza vaccine in patients with inflammatory bowel disease treated with immunomodulatory agents.

The investigations of efficacy and appropriate vaccination for trivalent influenza vaccine in patients with inflammatory bowel disease treated with immunomodulatory agents. - Optimization of trivalent influenza vaccination in IBD patients treated with immunomodulatory agents.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009259

Enrollment

128

Registered

2012-11-05

Start date

2012-11-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

two dose of vaccination single dose of vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: IBD patients: Crohn's disease, Ulcerative colitis, Intestinal Bechet's disease Healthy control:

Exclusion criteria

Exclusion criteria: 1) Pediatric IBD patients less than 12 years old 2) Patients who were recognized as inadequacy by doctor 3) Patients who had past history of adverse event for vaccination

Design outcomes

Primary

Measure	Time frame
The advantage for two dose of trivalent influenza vaccination compared to single dose vaccination in elder IBD patients or IBD patients treated with anti TNF-alpha agent or immunomodulator.	—

Secondary

Measure	Time frame
The comparison of the efficacy for trivalent influenza vaccination between IBD patients treated with immunomodulatory agents and healthy controls.	—

Countries

Japan

Contacts

Public ContactKenji Watanabe

Graduate School of Medicine, Osaka City University Department of Gastroenterology

kenjiw1779@gmail.com06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026